Organs-on-a-chip最新文献

Polydimethylsiloxane (PDMS) is among the most widely used materials for organ-on-chip systems. Despite its multiple beneficial characteristics from an engineering point of view, there is a concern about the effect of PDMS on the cells cultured in such devices. The aim of this study was to enhance the understanding of the effect of PDMS on cellular behavior in a context relevant for on-chip studies. The focus was put on an indirect effect of PDMS, namely leaching of uncrosslinked oligomers, particularly for bone regeneration applications. PDMS-based chips were prepared and analyzed for the potential release of PDMS oligomers within the microfluidic channel when kept at different flow rates. Leaching of uncrosslinked oligomers from PDMS was quantified as silicon concentration by inductively coupled plasma - optical emission spectrometry and further confirmed by mass spectrometry. Subsequently, PDMS-leached media, with a silicon concentration matching the on-chip experiment, were prepared to study cell proliferation and osteogenic differentiation of MC3T3-E1 pre-osteoblasts and human mesenchymal stem cells. The silicon concentration initially detected in the media was inversely proportional to the tested flow rates and decreased to control levels within 52 h. In addition, by curing the material overnight instead of 2 h, regardless of the curing temperature (65 and 80 °C), a large reduction in silicon concentration was found, indicating the importance of the PDMS curing parameters. Furthermore, it was shown that PDMS oligomers enhanced the differentiation of MC3T3-E1 pre-osteoblasts, this being a cell type dependent effect as no changes in cell differentiation were observed for human mesenchymal stem cells. Overall, this study illustrates the importance of optimization steps when using PDMS devices for biological studies, in particular PDMS curing conditions and extensive washing steps prior to an experiment.

Organ-on-a-chip is a microfluidic cell culture model that replicates key organ-specific microarchitecture and pathophysiology in vitro. The current methods to fabricate these devices rely on softlithography, which is usually tedious, laborious, and requires adroit users as well as cleanroom facilities. Recently, the use of 3D-printing technologies for the rapid fabrication of molds for polydimethylsiloxane (PDMS) casting is on the rise. However, most of the 3D-printed materials are unsuitable for PDMS casting. To address this issue, we have improved the existing techniques and introduced a modified protocol for the surface treatment of 3D-printed molds, making them ideal for repeated long-term PDMS casting. Using this protocol, we have fabricated a simple open well lung-on-a-chip model to simulate the in vivo environment of airway at air-liquid interface under dynamic condition. To validate the functionality of the developed chip, Calu-3 cells were cultured in the chip and maintained at an air-liquid interface. The model demonstrated that the cultured cells replicated the 3D culture-specific-morphology, maintained excellent barrier integrity, secreted mucus, and expressed cell surface functional P-glycoprotein; all indicative of a promising in vitro model for permeability assays, toxicological tests, and pulmonary drug delivery studies. To validate the suitability of this lung-on-a-chip in vitro model, the effects of cigarette smoke extract (CSE) on Interleukin-6 (IL-6) and Interleukin-8 (IL-8) release from cultured Calu-3 cells were examined. CSE treated cells showed significantly higher secretion of IL-6 and IL-8 over 24 h compared to the cells treated with both CSE and Budesonide, an anti-inflammatory drug. Moreover, our results illustrated that CSE reduced the expression of E-cadherin as an adherent junctional protein. In conclusion, the proposed protocol demonstrated an easy and low-cost fabrication technique which will allow a biologist with minimal technical skills to rapidly prototype molds for different/versatile organ-on-a-chip models.

Respiratory diseases such as asthma and COPD have no cures and few new treatments. These diseases have an immutable mortality rate and impact millions of individuals worldwide. Respiratory drug development is time-consuming and costly, owing to the inability of existing models to replicate the complexity of human disease (static cell cultures and animal models). The problem is intensified through the way in which drugs are delivered to these models, which is not always representative of the human microenvironment, where different drug delivery methods (impaction, sedimentation and diffusion) target different regions of the lungs. This review describes current models of the human airways together with the range of different aerosol drug delivery methods (commercially available and in development) alongside emerging Organ on Chip technologies.